National Health (October 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024

Overview

The National Health (October 2024 Flow on Price Reductions for Brands of Combination Items) (Exercise of Ministerial Discretion) Determination 2024, or PB 105 of 2024, was introduced to exercise ministerial discretion under the National Health Act 1953. This determination addresses the specific issue of ensuring that certain pharmaceutical brands' prices are not reduced as per the Act's requirements. Enacted by Nikolai Tsyganov, acting as the delegate of the Minister for Health and Aged Care, this instrument aims to maintain the approved ex-manufacturer prices of specified pharmaceutical items on 1 October 2024, as detailed in Schedule 1. The policy objective is to uphold the pricing integrity of particular combination drugs within the Pharmaceutical Benefits Scheme, thereby ensuring equitable access and affordability.

Scope and Application

The National Health (October 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024 applies to pharmaceutical brands listed in the Schedule of the instrument, specifically those whose ex-manufacturer prices are not to be reduced on 1 October 2024. This legislation falls under the purview of the National Health Act 1953 and is administered by the Minister for Health and Aged Care, with Nikolai Tsyganov acting as the delegate. The Act specifically targets the pharmaceutical industry, particularly the pricing of combination pharmaceutical items, and aims to regulate the flow-on effects of price reductions on such items. The jurisdictional reach of this Act is national, extending across the Commonwealth of Australia. The instrument does not explicitly state any exclusions, exemptions, or thresholds beyond those brands listed in Schedule 1 whose prices are not subject to reduction. The application of this Act is further governed by the Act itself, which may include provisions for subordinate instruments to refine or expand upon the primary legislation. These subordinate instruments allow for additional specifications or clarifications that may not be covered in the main Act, ensuring a comprehensive regulatory framework. This Determination ensures that certain brands of pharmaceutical items will maintain their approved ex-manufacturer prices, thereby influencing the pricing dynamics within the pharmaceutical market.

Key Provisions

The main operative sections of the National Health (October 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024 (referred to as PB 105 of 2024) provide specific details on the exercise of ministerial discretion under subsection 99ADHB(6) of the National Health Act 1953. The core provision (section 5) states that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in Schedule 1 is not reduced on 1 October 2024. This means that for the brands of pharmaceutical items listed, their prices will not decrease as of the specified date. The instrument also includes a definition section that clarifies terms used within the document, ensuring a common understanding of the terminology employed (section 4). The obligations and requirements imposed by this Act are primarily on the entities involved in the pricing of pharmaceutical items. For the brands of pharmaceutical items listed in Schedule 1, the determination mandates that their prices must remain unchanged as of the effective date. This is a clear directive from the Minister for Health and Aged Care, exercised by Nikolai Tsyganov as a delegate, to maintain the existing prices for these specific pharmaceutical items. This determination aims to control and stabilise the pricing of these essential drugs, ensuring that the cost does not reduce abruptly, which could impact the availability and affordability of these medications. In terms of offences, penalties, or consequences for breach, the determination itself does not explicitly state any penalties for non-compliance with the price maintenance directive. However, any failure to adhere to the ministerial determination could potentially lead to further regulatory action under the National Health Act 1953. Such actions might include administrative penalties, fines, or other enforcement measures to ensure compliance with the Act's provisions. While the specific penalties are not detailed in this determination, they would be determined based on the broader legislative framework under which the Act operates.